Protagonist Therapeutics Inc
$ 100.00
-2.55%
24 Apr - close price
- Market Cap 6,548,050,000 USD
- Current Price $ 100.00
- High / Low $ 105.94 / 98.91
- Stock P/E N/A
- Book Value 9.82
- EPS -2.05
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -0.20 %
- 52 Week High 107.84
- 52 Week Low 41.28
About
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Analyst Target Price
$113.33
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-18 | 2025-11-06 | 2025-08-06 | 2025-05-05 | 2025-02-25 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.69 | -0.62 | -0.55 | -0.19 | 1.98 | -0.54 | -0.5 | 3.26 | 0.44 | -0.58 | -0.68 | -0.67 |
| Estimated EPS | -0.3403 | -0.63 | -0.58 | 0.11 | 0.25 | -0.6 | -0.6 | 1.19 | -0.03 | -0.69 | -0.65 | -0.73 |
| Surprise | -0.3497 | 0.01 | 0.03 | -0.3 | 1.73 | 0.06 | 0.1 | 2.07 | 0.47 | 0.11 | -0.03 | 0.06 |
| Surprise Percentage | -102.7623% | 1.5873% | 5.1724% | -272.7273% | 692% | 10% | 16.6667% | 173.9496% | 1566.6667% | 15.942% | -4.6154% | 8.2192% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.65 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PTGX
2026-04-24 20:09:11
Protagonist Therapeutics, Inc.'s President and CEO, Dinesh V. Patel, Ph.D., reported a bona fide gift of 1,460 shares of Common Stock to family and friends. This transaction involved no monetary exchange, with a reported price of $0.00 per share. Following this gift, Patel directly holds 523,478 shares of Protagonist Therapeutics Common Stock.
2026-04-23 09:39:07
Protagonist Therapeutics (PTGX) has seen a 129% surge over the last year, prompting an evaluation of its current valuation. A Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 70.5% at its current price of $105.55, with an intrinsic value of $357.22 per share. While its Price to Book (P/B) ratio of 10.96x is above the industry average, the article concludes that the stock appears undervalued based on its cash flow projections.
2026-04-23 04:36:00
This article analyzes Protagonist Therapeutics Inc. (NASDAQ: PTGX) using AI models to inform risk allocation. It identifies a neutral near and mid-term outlook but a strong long-term positive bias, noting an exceptional 37.3:1 risk-reward setup. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels.
2026-04-22 11:40:22
Protagonist Therapeutics (Nasdaq:PTGX) is currently trading at US$102.62, which is 71.2% below Simply Wall St's estimate of its fair value. The company's earnings are forecast to grow by 41.37% per year, and its stock has seen significant price performance, with a 128.8% increase over the past year. Recent news highlights FDA acceptance of priority review for Rusfertide and a new drug application submission for the same, alongside positive clinical trial data for its pipeline products.
2026-04-21 23:09:11
Protagonist Therapeutics' CFO, Asif Ali, sold 1,750 shares of the company's stock for $184,572.50 to cover tax withholding obligations. This sale reduced his stake by 2.88% to 59,003 shares. Despite the insider selling and a recent earnings miss, Protagonist Therapeutics' stock is trading near its 1-year high, and analysts maintain a "Moderate Buy" rating with a consensus price target of $108.15.
2026-04-21 22:09:11
Protagonist Therapeutics CFO Ali Asif sold 1,750 shares of the company's common stock for $184,572 on April 20, 2026, to cover tax withholding obligations. Following the sale, Asif directly owns 59,003 shares, and the transaction occurred while the stock was near its 52-week high after a 130% return over the past year. InvestingPro analysis suggests the stock is currently overvalued, though analysts expect profitability this year.
